THE POTENTIAL USE of antibody for diagnostic or therapeutic applications in human cancer may well depend upon the ability to synthesize large quantities of monospecific "anti-tumour" immunoglobulin in vitro. In this respect, the hybridoma technology has produced murine monoclonal antibodies directed against a number of human tumour-associated antigens (Koprowski et al., 1978; Yeh et al., 1979; Kennett & Gilbert, 1979; Levy et al., 1979; Herlyn et al., 1979; Accolla et al., 1980) . However, the establishment of hybrid cell lines to produce human antibodies with defined tumour specificities has not yet been successful.
There is an alternative method for producing human antibody in vitro by infecting B lymphocytes with EpsteinBarr virus (EBV) to establish human lymphoblastoid cell lines. In 1977, Steinitz et al. and Luzzanti et al. first reported in vitro production of specific human antibody on the synthetic hapten NNP (4-hydroxy-3,5-dinitrophenacetic acid) and to heterologous erythrocytes, respectively, from EBV-transformed B lymphoblastoid cells. Following these studies, several other specific antibodies were produced in vitro by EBV transformation, including those to tetanus toxoid (Zurawski et al., 1978) , the hapten trinitrophenyl (TNP) (Kozbor et al., 1979) , the blood-group antigen Rh (Koskimies, 1979) and to diphtheria toxin (Tsuchiya et al., 1980) . We have successfully established lymphoblastoid cell lines that synthesize antibody directed against a human tumour-associated foetal antigen (TAFA) designated as Oncofoetal Antigen-I (OFA-I).
OFA-I, first described by our laboratory (Irie et al., 1976) , is a membrane antigen on various histological types of human cancer cells that cross-reacts with human foetal brain tissue, but has not been found in foetal liver, spleen, and thymus, or on any normal adult cells. OFA-I has been shown to be immunogenic in man, by its ability to provoke humoral antibody in patients with cancer using indirect membrane immunofluorescence (IMIF) (Irie et al., 1976) and immune-adherence (IA) (Irie et al., 1976 . Recently we reported that the disease-free interval of postoperative Stage II melanoma patients strongly correlates with their serum level of IgM anti-OFA-I (Jones et al., 1981) . This fact, coupled with the finding that serum anti-OFA-I is cytotoxic in the presence of either rabbit or human complement to OFA-I+ tumour cells (Sidell et al., 1979a, b) , suggests that IgM anti-OFA-I could confer some protection against tumour growth in vivo. The ability to produce IgM anti-OFA-I in vitro as described in this report should enable us to define more precisely the role of this TAFA in human cancer.
Ten serum samples containing high levels of anti-OFA-I antibody were first identified from more than 5000 serum samples that had been tested for anti-OFA-J specificity by IA or IMIF (Irie et al., 1976 Jones et al., 1981) by the dates of acquisition. Viably frozen peripheral-blood lymphocytes (PBL) to be transformed by EB virus were then matched to these 10 sera from the same individuals. The patient population in this study included 5 who received adjuvant immunotherapy with an OFA-I+ tumourcell vaccine (TCV), 3 who had been treated with BCG immunotherapy, and 2 who had had surgical excision but no adjuvant therapy. EB virus from the spent tissueculture medium of B-95-8 marmoset lymphoblastoid cells was used to transform 2 x 106 of the chosen PBL, as previously described (Irie et al., 1976; Miller & Lipmen, 1973) . Half the medium (RPMI with 100% foetal calf serum) was changed every 3rd day in each culture, and the volume was adjusted so that cell numbers were maintained at 2 x 105 cells/ml. Anti-OFA-J levels in the spent medium of each culture were monitored by IA using an OFA-I+ melanoma cell line, UCLA-SO-M14 (M14), as the target cell. Each procedure has been described (Irie et al., 1976 . The antibodytitre was defined as the reciprocal dilution at which 50°/0 of M14 target cells were involved in rosette formation with the human erythrocyte indicator cells (IA50). Reactivity to UCLA-SO-L14 (L14), a lymphoblastoid cell line autologous to the M14 donor, was also examined as an alloreactivity control (Saxton et al., 1978; Pellegrino et al., 1977) .
As shown in the figure, 2 of the EBV-infected cultures (ES from the TCV group and CD from the surgery-only group) produced detectable antibody to (Irie et al., 1976) . t M14 and L14, M1O and LIO, M18 and L18, and M15 and L15 were derived from same individuals, respectively, and shown to express identical HLA antigens (Pellegrino et al., 1977) . to L14. The DV lymphoblasts continued to produce increasing titres of anti-M14 antibody until Day 42, when the titre was 1: 32. This titre lasted for 6 days, gradually decreased to 1: 8 by Day 60, and became negative on Day 66. None of the other 7 PBL culture supernatants became positive toM14.
The specificity of the antibody to the Ml 4 melanoma cells in the DV spent medium was determined by absorption techniques (Irie et al., 1976) (Table I) . Absorption of supernatant with the L14 lymphoblasts did not decrease the antibody titre, confirming that the M14 reactivity was not due to antibody directed against HLA specificities (Saxton et al., 1978; Pellegrino et al., 1977) . However, peak anti-MI4 reactivity (1: 32 titre) could be completely abolished by absorption with OFA-I+ second-trimester human foetal brain tissue. Foetal liver tissue from the same foetus did not significantly reduce the antibody titre, indicating that the activity to M14 was due to anti-OFA-I (Irie et al., 1976) . This specificity was confirmed by absorption with a series of other OFA-I+ and OFA-1-tissues (Table   TABLE II An assessment of the immunoglobulin class produced in the DV culture was accomplished by using FITC-labelled monospecific goat antihuman IgG (y-chain specific), antihuman IgM (p-chain specific), or antihuman IgA (y-chain specific) as the second antibody in the IMIF, assay as described in Irie et al. (1979) . As indicated in Table II , more than 80% of the antibody-coated M14 target cells were stained by the goat antihuman IgM, while no cells were stained by antibodies to human IgG or IgA. Thus the anti-OFA-1 produced in this culture was apparently limited to the IgM class. This finding was consistent with the in vivo situation of donor DV, in whom only circulating IgM anti-OFA-1 was detected. Negative results using FITClabelled goat antibovine polyvalent Ig as the second antibody further confirmed that all the reactivity against M14 was due to human antibody and not to heterophile antibodies in the bovine serum used to supplement the DV lymphoblast culture medium.
Crucial for any further immunotherapeutic applications of in vitro-produced anti-OFA-1 is the need for these antibodies (Sidell et al., 1979b) demonstrated that the in vitro-produced anti-OFA-J, like serum anti-OFA-I, was cytotoxic in the presence of either rabbit or human complement (Table III) . No cytotoxicity was observed against OFA-1-M15 melanoma and L14 cells.
We concluded that the antibody produced by the DV lymphoblasts was of the IgM class, was monospecific for OFA-I (though not necessarily monoclonal) and could effectively lyse tumour cells expressing this antigen. The decrease of anti-M14 reactivity in the culture supernatants with time was frustrating. The same pheno-265 menon was also reported with tetanus antitoxin and diphtheria antitoxin produced by EBV-induced lymphoblastoid cell lines (Zurawski et al., 1978; Tsuchiya et al., 1980) . Further efforts are now under way to establish lymphoblastoid cell lines that will permanently produce anti-OFA-I, as well as to isolate highly active subclones from the DV lymphoblastoid cells which were cryopreserved at the time of peak antibody reactivity. These earlypassage cell cultures demonstrate anti-OFA-J titres of 1: 16-32 within 3 days of thawing. In any case, the ease of establishing anti-OFA-1-producing lymphoblastoid cell lines from the PBL of patients with high titres of circulating anti-OFA-1 should allow us to obtain ample amounts of homogeneous antibody for further characterization of the OFA-J antigenantibody system. These investigations were supported by Grant CA12582 from the National Cancer Institute (DHEW) and the Medical Research Service of the Veterans Administration. Dr Irie is a recipient of a Research Career Development Award, CA00543, from the National Cancer Institute.
